Compare Gilead Sciences, Inc. (GILD) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sezzle Inc — how do they compare? Gilead Sciences, Inc. trades at $134.49 (market cap $163.51B), while Sezzle Inc trades at $188.69 (market cap $6.34B). The key difference: Gilead Sciences, Inc. is far larger — about 25.8× Sezzle Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals.
| GILD | SEZL | |
|---|---|---|
Market Cap | $163.51B | $6.34B |
Sector | Health | Technology |
52-Week High | $155.80 | $188.55 |
52-Week Low | $108.22 | $50.97 |
Enterprise Value | $178.05B | $6.37B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Sezzle (SEZL) trades at $193.51, up 6.1% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and trades above key resistance at $194. Fundamentally, the company demonstrates impressive profitability with 30.83% net margins and 91.95% ROE, supported by consistent earnings beats in recent quarters. Recent news highlights product expansion and raised 2026 guidance following strong Q1 results.
Outlook remains positive with accelerating revenue growth and expanding profitability, though valuation multiples appear elevated. Key risks include competitive pressures in fintech and ongoing securities investigation. Analyst consensus is split with 50% buy ratings but average price target of $162 suggests caution about current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
